Trelagliptin succinate

Names

[ Name ]:
Trelagliptin succinate

[Synonym ]:
Trelagliptin (succinate)
Trelagliptin succinate [USAN]
Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluoro-, butanedioate (1:1)
SYR472 succinate
Zafatek
SYR 472
2-({[6-[(3R)-3-aminopipidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)- yl}methyl)-4-fluorobenzonitrile hydrogen butanedioate
Succinic acid - 2-({6-[(3R)-3-amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorobenzonitrile (1:1)
SYR111472 Succinate
SYR-472

Biological Activity

[Description]:

Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.

[Related Catalog]:

Signaling Pathways >> Metabolic Enzyme/Protease >> Dipeptidyl Peptidase

Research Areas >> Metabolic Disease

[References]

[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

[2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

[3]. Long-term Study of SYR-472

[4]. SYR-472 Open-label Study

[Related Small Molecules]